Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Conditions: Urologic Neoplasms; Urogenital Neoplasms; Male Urogenital Diseases; Penile Cancer; Penile Squamous Cell Carcinoma; Locally Advanced Penile Carcinoma Interventions: Drug: Carboplatin/Paclitaxel; Drug: Pembrolizumab; Procedure: Partial or total penectomy with inguinal and/or pelvic lymph node dissection Sponsors: The Netherlands Cancer Institute; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Conditions: Metastatic Penile Squamous Cell Carcinoma; Stage III Penile Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Unresectable Penile Squamous Cell Carcinoma Interventions: Drug: Enfortumab Vedotin Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Molecular Characterization of Penile Cancers in Developing Countries
Conditions: Penile Squamous Cell Carcinoma Sponsors: Latin American Cooperative Oncology Group; Roche Pharma AG Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Conditions: Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Carcinoma of Vagina; Carcinoma of Penis; Anal Cancer; Carcinoma of Vulva Interventions: Biological: HRYZ-T101 Injection; Drug: Fludarabine + Cyclophosphamide Sponsor: SYZ Cell Therapy Co.. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2023 Category: Research Source Type: clinical trials
